DSGN Q4 2023 Earnings — Design Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

DSGNDesign Therapeutics, Inc.

$569M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$15M

Net Income

-$12M

EPS (Diluted)

$-0.21

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$290M

Total Liabilities

$12M

Stockholders' Equity

$278M

Cash & Equivalents

$21M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$15M	-$19M	+22.0%
Net Income	-$12M	-$17M	+31.7%